Patents by Inventor John Anthony Zuris

John Anthony Zuris has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12325854
    Abstract: CRISPR/Cpf1-related compositions and methods for treatment of cancer.
    Type: Grant
    Filed: September 4, 2018
    Date of Patent: June 10, 2025
    Assignee: EDITAS MEDICINE, INC.
    Inventors: Gordon Grant Welstead, Hariharan Jayaram, Tongyao Wang, John Anthony Zuris, Christopher Borges
  • Publication number: 20250025572
    Abstract: The present disclosure relates to Cast 2a effector proteins with increased activity compared to previously described Cas12a effector proteins. The present disclosure also relates to fusion proteins comprising a Cas12a effector protein fused to a deaminase with increased activity compared to previously described fusion proteins comprising a Cast 12a effector protein fused to a deaminase. Systems and methods of their use are also disclosed.
    Type: Application
    Filed: November 28, 2022
    Publication date: January 23, 2025
    Inventor: John Anthony Zuris
  • Publication number: 20240293543
    Abstract: Edited cells, e.g., genomically edited cells, with reduced levels of immune rejection and/or improved persistence are described.
    Type: Application
    Filed: June 23, 2022
    Publication date: September 5, 2024
    Inventor: John Anthony Zuris
  • Patent number: 12049651
    Abstract: Disclosed herein are enzymatically active Cas9 (eaCas9) fusion molecules, comprising an eaCas9 molecule linked, e.g., covalently or non-covalently, to a template nucleic acid; gene editing systems comprising the eaCas9 fusion molecules, and methods of use thereof.
    Type: Grant
    Filed: December 20, 2021
    Date of Patent: July 30, 2024
    Assignee: Editas Medicine, Inc.
    Inventors: Cecilia Cotta-Ramusino, Hariharan Jayaram, John Anthony Zuris
  • Patent number: 12031132
    Abstract: Genome editing systems, guide RNAs, and CRISPR-mediated methods are provided for altering portions of the HBG1 and HBG2 loci, portions of the erythroid specific enhancer of the BCL11A gene, or a combination thereof, in cells and increasing expression of fetal hemoglobin.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: July 9, 2024
    Assignee: EDITAS MEDICINE, INC.
    Inventors: Jennifer Leah Gori, Edouard Aupepin De Lamothe-Dreuzy, Jack Heath, John Anthony Zuris, KaiHsin Chang
  • Publication number: 20240117383
    Abstract: Strategies, systems, compositions, and methods for efficient production of knock-in cellular clones without reporter genes. An essential gene is targeted using a knock-in cassette that comprises an exogenous coding sequence for a gene product of interest (or “cargo sequence”) in frame with and downstream (3?) of an exogenous coding sequence or partial coding sequence of the essential gene. Undesired targeting events create a non-functional version of the essential gene, in essence a knock-out, which is “rescued” by correct integration of the knock-in cassette, which restores the essential gene coding region so that a functional gene product is produced and positions the cargo sequence in frame with and downstream of the essential gene coding sequence.
    Type: Application
    Filed: December 12, 2023
    Publication date: April 11, 2024
    Inventors: John Anthony Zuris, Carrie Marie Margulies
  • Publication number: 20230227856
    Abstract: Strategies, systems, compositions, and methods for efficient production of knock-in cellular clones without reporter genes. An essential gene is targeted using a knock-in cassette that comprises an exogenous coding sequence for a gene product of interest (or “cargo sequence”) in frame with and downstream (3?) of an exogenous coding sequence or partial coding sequence of the essential gene. Undesired targeting events create a non-functional version of the essential gene, in essence a knock-out, which is “rescued” by correct integration of the knock-in cassette, which restores the essential gene coding region so that a functional gene product is produced and positions the cargo sequence in frame with and downstream of the essential gene coding sequence.
    Type: Application
    Filed: May 4, 2021
    Publication date: July 20, 2023
    Inventors: John Anthony Zuris, Carrie Marie Margulies, Chew-Li Soh, Peter Tonge, Mark James Tomishima, Conor Brian McAuliffe, Claudio Monetti
  • Publication number: 20220186199
    Abstract: Disclosed herein are enzymatically active Cas9 (eaCas9) fusion molecules, comprising an eaCas9 molecule linked, e.g., covalently or non-covalently, to a template nucleic acid; gene editing systems comprising the eaCas9 fusion molecules, and methods of use thereof.
    Type: Application
    Filed: December 20, 2021
    Publication date: June 16, 2022
    Inventors: Cecilia Cotta-Ramusino, Hariharan Jayaram, John Anthony Zuris
  • Patent number: 11236313
    Abstract: Disclosed herein are enzymatically active Cas9 (eaCas9) fusion molecules, comprising an eaCas9 molecule linked, e.g., covalently or non-covalently, to a template nucleic acid; gene editing systems comprising the eaCas9 fusion molecules, and methods of use thereof.
    Type: Grant
    Filed: April 12, 2017
    Date of Patent: February 1, 2022
    Assignee: Editas Medicine, Inc.
    Inventors: Cecilia Cotta-Ramusino, Hariharan Jayaram, John Anthony Zuris
  • Publication number: 20210315994
    Abstract: Compositions, methods, strategies, kits, and systems for the delivery of negatively charged proteins, protein complexes, and fusion proteins, using cationic polymers or lipids are provided. Delivery of proteins into cells can be effected in vivo, ex vivo, or in vitro. Proteins that can be delivered using the compositions, methods, strategies, kits, and systems provided herein include, without limitation, enzymes, transcription factors, genome editing proteins, Cas9 proteins, TALEs, TALENs, nucleases, binding proteins (e.g., ligands, receptors, antibodies, antibody fragments; nucleic acid binding proteins, etc.), structural proteins, and therapeutic proteins (e.g., tumor suppressor proteins, therapeutic enzymes, growth factors, growth factor receptors, transcription factors, proteases, etc.), as well as variants and fusions of such proteins.
    Type: Application
    Filed: December 22, 2020
    Publication date: October 14, 2021
    Applicant: President and Fellows of Harvard College
    Inventors: David R. Liu, David B. Thompson, John Anthony Zuris
  • Patent number: 10912833
    Abstract: Compositions, methods, strategies, kits, and systems for the delivery of negatively charged proteins, protein complexes, and fusion proteins, using cationic polymers or lipids are provided. Delivery of proteins into cells can be effected in vivo, ex vivo, or in vitro. Proteins that can be delivered using the compositions, methods, strategies, kits, and systems provided herein include, without limitation, enzymes, transcription factors, genome editing proteins, Cas9 proteins, TALEs, TALENs, nucleases, binding proteins (e.g., ligands, receptors, antibodies, antibody fragments; nucleic acid binding proteins, etc.), structural proteins, and therapeutic proteins (e.g., tumor suppressor proteins, therapeutic enzymes, growth factors, growth factor receptors, transcription factors, proteases, etc.), as well as variants and fusions of such proteins.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: February 9, 2021
    Assignee: President and Fellows of Harvard College
    Inventors: David R. Liu, David B. Thompson, John Anthony Zuris
  • Publication number: 20200323984
    Abstract: Compositions, methods, strategies, kits, and systems for the supercharged protein-mediated delivery of functional effector proteins into cells in vivo, ex vivo, or in vitro are provided. Compositions, methods, strategies, kits, and systems for delivery of functional effector proteins using cationic lipids and cationic polymers are also provided. Functional effector proteins include, without limitation, transcriptional modulators (e.g., repressors or activators), recombinases, nucleases (e.g., RNA-programmable nucleases, such as Cas9 proteins; TALE nuclease, and zinc finger nucleases), deaminases, and other gene modifying/editing enzymes. Functional effector proteins include TALE effector proteins, e.g., TALE transcriptional activators and repressors, as well as TALE nucleases.
    Type: Application
    Filed: April 28, 2020
    Publication date: October 15, 2020
    Applicant: President and Fellows of Harvard College
    Inventors: Daivd R. Liu, John Anthony Zuris, David B. Thompson
  • Patent number: 10682410
    Abstract: Compositions, methods, strategies, kits, and systems for the supercharged protein-mediated delivery of functional effector proteins into cells in vivo, ex vivo, or in vitro are provided. Compositions, methods, strategies, kits, and systems for delivery of functional effector proteins using cationic lipids and cationic polymers are also provided. Functional effector proteins include, without limitation, transcriptional modulators (e.g., repressors or activators), recombinases, nucleases (e.g., RNA-programmable nucleases, such as Cas9 proteins; TALE nuclease, and zinc finger nucleases), deaminases, and other gene modifying/editing enzymes. Functional effector proteins include TALE effector proteins, e.g., TALE transcriptional activators and repressors, as well as TALE nucleases.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: June 16, 2020
    Assignee: President and Fellows of Harvard College
    Inventors: David R. Liu, John Anthony Zuris, David B. Thompson
  • Publication number: 20190136210
    Abstract: Disclosed herein are enzymatically active Cas9 (eaCas9) fusion molecules, comprising an eaCas9 molecule linked, e.g., covalently or non-covalently, to a template nucleic acid; gene editing systems comprising the eaCas9 fusion molecules, and methods of use thereof.
    Type: Application
    Filed: April 12, 2017
    Publication date: May 9, 2019
    Inventors: Cecilia Cotta-Ramusino, Hariharan Jayaram, John Anthony Zuris
  • Patent number: 10258697
    Abstract: Compositions are described for direct protein delivery into multiple cell types in the mammalian inner ear. The compositions are used to deliver protein(s) (such as gene editing factors) editing of genetic mutations associated with deafness or associated disorders thereof. The delivery of genome editing proteins for gene editing and correction of genetic mutations protect or restore hearing from genetic deafness. Methods of treatment include the intracellular delivery of these molecules to a specific therapeutic target.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: April 16, 2019
    Assignee: Massachusetts Eye and Ear Infirmary
    Inventors: Zheng-Yi Chen, David Liu, John Anthony Zuris, David B. Thompson
  • Publication number: 20190062735
    Abstract: CRISPR/Cpf1-related compositions and methods for treatment of cancer.
    Type: Application
    Filed: September 4, 2018
    Publication date: February 28, 2019
    Applicant: EDITAS MEDICINE, INC.
    Inventors: Gordon Grant Welstead, Hariharan Jayaram, Tongyao Wang, John Anthony Zuris, Christopher Borges
  • Publication number: 20180236081
    Abstract: Compositions, methods, strategies, kits, and systems for the delivery of negatively charged proteins, protein complexes, and fusion proteins, using cationic polymers or lipids are provided. Delivery of proteins into cells can be effected in vivo, ex vivo, or in vitro. Proteins that can be delivered using the compositions, methods, strategies, kits, and systems provided herein include, without limitation, enzymes, transcription factors, genome editing proteins, Cas9 proteins, TALEs, TALENs, nucleases, binding proteins (e.g., ligands, receptors, antibodies, antibody fragments; nucleic acid binding proteins, etc.), structural proteins, and therapeutic proteins (e.g., tumor suppressor proteins, therapeutic enzymes, growth factors, growth factor receptors, transcription factors, proteases, etc.), as well as variants and fusions of such proteins.
    Type: Application
    Filed: April 20, 2018
    Publication date: August 23, 2018
    Applicant: President and Fellows of Harvard College
    Inventors: David R. Liu, David B. Thompson, John Anthony Zuris
  • Patent number: 9999671
    Abstract: Compositions, methods, strategies, kits, and systems for the delivery of negatively charged proteins, protein complexes, and fusion proteins, using cationic polymers or lipids are provided. Delivery of proteins into cells can be effected in vivo, ex vivo, or in vitro. Proteins that can be delivered using the compositions, methods, strategies, kits, and systems provided herein include, without limitation, enzymes, transcription factors, genome editing proteins, Cas9 proteins, TALEs, TALENs, nucleases, binding proteins (e.g., ligands, receptors, antibodies, antibody fragments; nucleic acid binding proteins, etc.), structural proteins, and therapeutic proteins (e.g., tumor suppressor proteins, therapeutic enzymes, growth factors, growth factor receptors, transcription factors, proteases, etc.), as well as variants and fusions of such proteins.
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: June 19, 2018
    Assignee: President and Fellows of Harvard College
    Inventors: David R. Liu, David B. Thompson, John Anthony Zuris
  • Patent number: 9737604
    Abstract: Compositions, methods, strategies, kits, and systems for the supercharged protein-mediated delivery of functional effector proteins into cells in vivo, ex vivo, or in vitro are provided. Compositions, methods, strategies, kits, and systems for delivery of functional effector proteins using cationic lipids and cationic polymers are also provided. Functional effector proteins include, without limitation, transcriptional modulators (e.g., repressors or activators), recombinases, nucleases (e.g., RNA-programmable nucleases, such as Cas9 proteins; TALE nuclease, and zinc finger nucleases), deaminases, and other gene modifying/editing enzymes. Functional effector proteins include TALE effector proteins, e.g., TALE transcriptional activators and repressors, as well as TALE nucleases.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: August 22, 2017
    Assignee: President and Fellows of Harvard College
    Inventors: David R. Liu, John Anthony Zuris, David B. Thompson
  • Patent number: 9526784
    Abstract: Compositions, methods, strategies, kits, and systems for the supercharged protein-mediated delivery of functional effector proteins into cells in vivo, ex vivo, or in vitro are provided. Compositions, methods, strategies, kits, and systems for delivery of funcational effector proteins using cationic lipids and cationic polymers are also provided. Functional effector proteins include, without limitation, transcriptional modulators (e.g., repressors or activators), recombinases, nucleases (e.g., RNA-programmable nucleases, such as Cas9 proteins; TALE nuclease, and zinc finger nucleases), deaminases, and other gene modifying/editing enzymes. Functional effector proteins include TALE effector proteins, e.g., TALE transcriptional activators and repressors, as well as TALE nucleases.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: December 27, 2016
    Assignee: President and Fellows of Harvard College
    Inventors: David R. Liu, John Anthony Zuris, David B. Thompson